Article Text

Download PDFPDF
Randomised Controlled Trial
Low-dose rosiglitazone plus metformin reduces risk of incident type 2 diabetes compared with placebo in people with impaired glucose tolerance

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Competing interests PDH provides educational, advisory and research services in association with the manufacturer of rosiglitazone.